Prostate Cancer

>

Latest News

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.
Early Efficacy Seen With Gedatolisib-Based Therapies Prostate/Breast Cancers

June 30th 2025

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.

225Ac-LNC1011 targeted α therapy elicited an ORR of 50.0% in patients with PSMA-positive prostate cancer in a phase 1 trial.
Novel Targeted Therapy Shows Promise in PSMA-Positive Prostate Cancer

June 24th 2025

A retrospective study shows that [177Lu]Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.
Radioligand Therapy Retreatment Shows Promise in Metastatic CRPC

June 23rd 2025

The FDA did not expand the indication to include patients with non-homologous recombination-repair gene-mutated castration-resistant prostate cancer.
FDA Accepts sNDA for Talazoparib/Enzalutamide in HRR-Mutant mCRPC

June 18th 2025

Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC
Olaparib/Radium-223 Combination Demonstrates Feasibility and Antitumor Activity in CRPC

June 4th 2025

More News